Breaking Down Barriers In Immune-Excluded Tumor Biology

Time: 4:15 pm
day: Day Two


  • Immune exclusion in tumors has been associated with unfavorable clinical outcome and poor response to therapy
  • Therapies targeting immune exclusion are orthogonal to cancer immunotherapy and could improve responses
  • DDR1 as an example of a druggable target implicated in establishing mechanical barriers for an immune response